OTTAWA, Ontario, June 20, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd., today announced new preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in colorectal cancer.
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
Leave us a message and we will try to respond by the next business day
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4
CANADA
info@orionbiotechnology.com
+1 343.291.1032
This website uses cookies to ensure you get the best experience on our site. By using this website, you agree to our use of cookies.
Leave us a message and we will try to respond by the next business day
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4
CANADA
info@orionbiotechnology.com
+1 343.291.1032
